Alterity Therapeutics announced the European Patent Office has granted Alterity a new composition of matter patent. The patent secures broad protection over a new class of iron chaperone drug candidates for treating major neurodegenerative diseases. It is well established that excess iron in the brain is implicated in the pathology of many important neurodegenerative diseases, including Alzheimer?s and Parkinson?s diseases.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0055 AUD | +10.00% | -8.33% | -21.43% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.43% | 17.33M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- ATH Stock
- News Alterity Therapeutics Limited
- Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's